Efficacy and safety of combination therapies vs monotherapy of hypomethylating agents in accelerated or blast phase of Philadelphia negative myeloproliferative neoplasms: a systematic review and meta-analysis

BACKGROUND: There is a lack of evidence regarding whether combination therapy of hypomethylating agents (HMAs) has better outcomes than HMA monotherapy in patients with Philadelphia chromosome-negative accelerated or blast phase myeloproliferative neoplasms (MPN-AP/BP). MATERIALS AND METHODS: Pubmed...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jia, Wang, Kefei, Xiao, Zhijian, Xu, Zefeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2023
Materias:
Hematology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848335/
https://www.ncbi.nlm.nih.gov/pubmed/36644935
http://dx.doi.org/10.1080/07853890.2022.2164611

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9848335/
https://www.ncbi.nlm.nih.gov/pubmed/36644935
http://dx.doi.org/10.1080/07853890.2022.2164611

Ejemplares similares